SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Storey Robert F.)
 

Search: WFRF:(Storey Robert F.) > (2010-2014) > Biomarkers in Relat...

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

Wallentin, Lars (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Lindholm, Daniel (author)
Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
Siegbahn, Agneta (author)
Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
show more...
Wernroth, Lisa (author)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
Becker, Richard C. (author)
Cannon, Christopher P. (author)
Cornel, Jan H. (author)
Himmelmann, Anders (author)
Giannitsis, Evangelos (author)
Harrington, Robert A. (author)
Held, Claes (author)
Husted, Steen (author)
Katus, Hugo A. (author)
Mahaffey, Kenneth W. (author)
Steg, Ph. Gabriel (author)
Storey, Robert F. (author)
James, Stefan K. (author)
show less...
 (creator_code:org_t)
2014
2014
English.
In: Circulation. - 0009-7322 .- 1524-4539. ; 129:3, s. 293-303
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background Risk stratification and the use of specific biomarkers have been proposed for tailoring treatment in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). We investigated the prognostic importance of high-sensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) in relation to randomized treatment (ticagrelor versus clopidogrel) and management strategy (with or without revascularization) in the NSTE-ACS subgroup of the Platelet Inhibition and Patient Outcomes (PLATO) trial. Methods and Results Of 18 624 patients in the PLATO trial, 9946 had an entry diagnosis of NSTE-ACS and baseline blood samples available. During index hospitalization, 5357 were revascularized, and 4589 were managed without revascularization. Hs-TnT, NT-proBNP, and GDF-15 were determined and assessed according to predefined cutoff levels. Median follow-up was 9.1 months. Increasing levels of hs-TnT were associated with increasing risk of cardiovascular death, myocardial infarction, and stroke in medically managed patients (P<0.001), but not in those managed invasively. NT-proBNP and GDF-15 levels were associated with the same events independent of management strategy. Ticagrelor versus clopidogrel reduced the rate of cardiovascular death, myocardial infarction, and stroke in patients with NSTE-ACS and hs-TnT 14.0 ng/L in both invasively and noninvasively managed patients; in patients with hs-TnT <14.0 ng/L, there was no difference between ticagrelor and clopidogrel in the noninvasive group Conclusions Hs-TnT, NT-proBNP, and GDF-15 are predictors of cardiovascular death, myocardial infarction, and stroke in patients with NSTE-ACS managed noninvasively, and NT-proBNP and GDF-15 also in those managed invasively. Elevated hs-TnT predicts substantial benefit of ticagrelor over clopidogrel both in invasively and noninvasively managed patients, but no apparent benefit was seen at normal hs-TnT. Clinical Trial Registration URL:http://www.clinicaltrials.gov. Unique identifier: NCT00391872.

Keyword

acute coronary syndrome
biological markers
blood platelets
myocardial infarction
troponin

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view